HC Wainwright Keeps Price Targets on Aclaris, Connect Biopharma and Neurogene
HC Wainwright & Co. maintained price targets: $16.00 for Aclaris Therapeutics, $7.00 for Connect Biopharma, $65.00 for Neurogene. Source: Dow Jones Newswires.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
HC Wainwright & Co. kept its price targets unchanged for three biotech companies: $16.00 a share for Aclaris Therapeutics, $7.00 for Connect Biopharma and $65.00 for Neurogene. The information comes from Dow Jones Newswires, which cites Benzinga ratings data.
Such reiterations are routine and rarely move the broader market. Investors usually read them as a sign the brokerage sees no change in its valuation of these stocks.
why it matters
For markets this is a routine event: keeping a price target does not signal a rise or fall relative to current quotes. Company revenue and news about their drug pipelines carry far more weight, and the targets should be seen as one opinion among many.
tags
instruments
sources
- Aclaris Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co. — Dow Jones Newswires, 28 October 2026 at 11:08 UTC
- Connect Biopharma Price Target Maintained With a $7.00/Share by HC Wainwright & Co. — Dow Jones Newswires, 28 October 2026 at 11:49 UTC
- Neurogene Price Target Maintained With a $65.00/Share by HC Wainwright & Co. — Dow Jones Newswires, 28 October 2026 at 11:47 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗